Breast cancer is the most-researched disease, yet only 14% of trials reach optimal enrollment, highlighting a significant gap in clinical trial participation. COVID-19 has increased trial attrition ...
The FDA has approved revumenib (Revuforj; Syndax Pharmaceuticals) for patients aged 1 year and older with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback